Neural stem cell transplantation as an alternative therapy for neurodegenerative diseases.
The increasing life expectancy of the world population requires more effective treatments for neurodegenerative diseases, which are common in the elderly, such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS) [ref. 1]. Neural stem cells (NSCs) are essential for the development and maintenance of the function of the nervous system and have a broad therapeutic role in neurodegenerative diseases.
NSCs are cells that can self-renew and have the potential to differentiate into neurons, astrocytes, and oligodendrocytes [ref. 2]. The properties of neural stem cells are summarized as follows: (i) Generation of neural tissue [ref. 3]. (ii) Self-renewal capacity. (iii) Multipotential differentiation. (iv) Low immunogenicity. The discovery of neural stem cells shattered the conventional notion that “neurons do not regenerate” [ref. 4].
The damage and death of neurons and glial cells after CNS injury or degeneration leads to the corresponding clinical symptoms. It is difficult to perform effective neuronal and glial cell repair due to the limited number of neural stem cells and the impermissible microenvironment in the brain, so stem cell transplantation therapy has a promising future in this regard [ref. 5].
To obtain scalable and well-characterized subpopulations of NSCs from pluripotent stem cells, such as human embryonic stem cells (hESCs) or induced pluripotent stem cells (iPSCs), different NSC differentiation protocols have been developed [ref. 6]. The commonly used protocol is based on the generation of embryoid bodies (EBs) that adhere and expand in serum-free medium containing growth factors, such as fibroblast growth factor (FGF), epidermal growth factor (EGF), neurotrophic factors (NTF) ,etc. This not only stimulates the differentiation of NSCs into linear cell populations, but also reduces cell death in host endogenous neurons, promotes their axonal/dendritic connections, and enhances the survival and engraftment of transplanted NSCs [ref. 7].
| Product name | Description |
|---|---|
| Brain-derived neurotrophic factor (BDNF) (HY-P7116A) | Neurotrophic factor |
| Vascular endothelial growth factor (VEGF) (HY-P73471) | Angiogenic signaling protein |
| Glial-cell-line-derived neurotrophic factor (GDNF) (HY-P73075) | Neurotrophic factor |
| Nerve growth factor (NGF) (HY-P7660) | Neurotrophic factor and neuropeptide |
| Neurotrophin-3 (NT3) (HY-P70456) | Neurotrophic factor |
| Basic fibroblast growth factor (BFGF) (HY-P7330) | Mitogenic factor |
| Epidermal growth factor (EGF) (HY-P7109) | Mitogenic factor |
| Insulin-like growth factor-1 (IGF-1) (HY-P70698A) | Protein hormone |
| Insulin-like growth factor-2 (IGF-2) (HY-P70950) | Protein hormone |
| Ciliary neurotrophic factor (CNTF) (HY-P7146) | Neurotrophic factor |
MCE offers a comprehensive collection of TNF superfamily, TGF-beta superfamily, neurotrophic factors as well as other cytokines and growth factors for your research. MCE also has over 10,000 recombinant proteins and protein customization services.
Screening Libraries | Chemicals & Biochemicals | Recombinant Proteins | Assay Kits | PCR | Signaling Pathways | Dyes | Inhibitors | HNMR, LC-MS, HPLC, Stability Testing
We gladly support you by keeping you updated on our latest products and developments